Published in Int J STD AIDS on August 01, 2010
Human immunodeficiency virus infection and the liver. World J Hepatol (2012) 0.98
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS One (2012) 0.97
Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci (2011) 0.92
Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects. J Acquir Immune Defic Syndr (2014) 0.87
Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco. World J Hepatol (2013) 0.78
Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature. BMC Infect Dis (2012) 0.78
The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection. J Res Med Sci (2015) 0.77
Prevalence of hepatitis B and C and relationship to liver damage in HIV infected patients attending Joint Clinical Research Centre Clinic (JCRC), Kampala, Uganda. Afr Health Sci (2015) 0.76
Alcohol Interactive Toxicity Beliefs and ART Non-adherence Among HIV-Infected Current Drinkers in Mbarara, Uganda. AIDS Behav (2016) 0.75
Hepatitis B serological markers and plasma DNA concentrations. AIDS (2017) 0.75
Association of Abnormal Liver Function Parameters with HIV Serostatus and CD4 Count in Antiretroviral-Naive Rwandan Women. AIDS Res Hum Retroviruses (2015) 0.75
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS (2007) 3.19
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis (2005) 2.91
Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis (2009) 2.82
Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology (2007) 2.34
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int (2005) 1.74
Management of hepatic complications in HIV-infected persons. J Infect Dis (2008) 1.42
Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.40
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci (2008) 1.25
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology (2005) 1.17
Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci (2007) 1.07
Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda. J Med Virol (2010) 1.03
Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda. AIDS Patient Care STDS (2008) 0.97
Seroprevalence and biochemical features of hepatitis B surface antigenemia in patients with HIV-1 infection in Lagos, Nigeria. Afr J Med Med Sci (2006) 0.94
Description of liver disease in a cohort of HIV/HBV coinfected patients. J Clin Virol (2009) 0.93
Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev (2007) 0.92
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health (2010) 0.89
Elevated liver enzymes following initiation of antiretroviral therapy JAMA (2000) 0.88
Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med (2008) 0.88
Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance. Int J STD AIDS (2008) 0.81
[Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy]. Med Clin (Barc) (2001) 0.80
Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis (1999) 5.59
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med (2000) 4.83
Glanders in a military research microbiologist. N Engl J Med (2001) 4.77
Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis (1999) 4.18
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology (1999) 4.11
Use of specialised isolation media for recognition and identification of Candida dubliniensis isolates from HIV-infected patients. Eur J Clin Microbiol Infect Dis (1997) 3.86
Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 3.68
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS (1999) 3.67
Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis (2000) 3.01
Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab (1999) 2.98
Epidemiologic and clinical aspects of the Ebola virus epidemic in Mosango, Democratic Republic of the Congo, 1995. J Infect Dis (1999) 2.70
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol (1997) 2.55
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
Rolling out antiretrovirals in Africa: there are still challenges ahead. Clin Infect Dis (2005) 2.43
HIV testing in developing countries. Lancet (1997) 2.19
Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis (1999) 2.06
Hepatitis E: an emerging infectious disease. Epidemiol Rev (1999) 2.04
Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol (1999) 1.98
Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis (2000) 1.87
Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis (1999) 1.86
Mechanism of cellulose synthesis in Agrobacterium tumefaciens. J Bacteriol (1995) 1.80
Chronic viral hepatitis and the human genome. Hepatology (2000) 1.79
Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis (2001) 1.75
Recurrence of blackwater fever: triggering of relapses by different antimalarials. Trop Med Int Health (1998) 1.75
A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.74
Syphilis serology in human immunodeficiency virus infection: evidence for false-negative fluorescent treponemal testing. J Infect Dis (1997) 1.74
Ebola outbreak in Kikwit, Democratic Republic of the Congo: discovery and control measures. J Infect Dis (1999) 1.73
Dihydroxyacetone phosphate. Its structure and reactivity with -glycerophosphate dehydrogenase, aldolase and triose phosphate isomerase and some possible metabolic implications. Biochem J (1971) 1.73
Respiratory dysfunction in swine production facility workers: dose-response relationships of environmental exposures and pulmonary function. Am J Ind Med (1995) 1.64
Improvement of the patient flow in a large urban clinic with high HIV seroprevalence in Kampala, Uganda. Int J STD AIDS (2009) 1.59
Vaccines to prevent viral hepatitis. N Engl J Med (1997) 1.58
Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet (2001) 1.58
Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single-and double-stranded DNAs. J Clin Microbiol (1998) 1.53
Field evaluation of five rapid diagnostic tests for screening of HIV-1 infections in rural Rakai, Uganda. Int J STD AIDS (2011) 1.49
Class II HLA alleles and hepatitis B virus persistence in African Americans. J Infect Dis (1999) 1.48
Inheritance and variation in eggshell patterning in the great tit Parus major. Proc Biol Sci (2000) 1.47
Development of a high-resolution fat and CSF-suppressed optic nerve DTI protocol at 3T: application in multiple sclerosis. Funct Neurol (2013) 1.46
Survey among survivors of the 1995 Ebola epidemic in Kikwit, Democratic Republic of Congo: their feelings and experiences. Trop Med Int Health (1998) 1.44
Ebola hemorrhagic fever and pregnancy. J Infect Dis (1999) 1.41
Protein fluorescence of nicotinamide nucleotide-dependent dehydrogenases. Biochem J (1972) 1.40
Euthanasia: from the perspective of HIV infected persons in Europe. HIV Med (2001) 1.40
Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol (1999) 1.40
Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet (1998) 1.39
Efficacy of octreotide in the management of chronic diarrhoea in AIDS. AIDS (1992) 1.39
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Primary care involvement in human immune deficiency virus infection-a pan-European view. The Eurosupport Study Group. Fam Pract (2000) 1.37
Dose-response relationships between occupational aerosol exposures and cross-shift declines of lung function in poultry workers: recommendations for exposure limits. J Occup Environ Med (2000) 1.36
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS (2001) 1.35
Tuberculosis knowledge, attitudes and health-seeking behaviour in rural Uganda. Int J Tuberc Lung Dis (2011) 1.35
Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis (2005) 1.35
Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV. J Virol (2001) 1.34
High resolution MRI of the brain at 4.7 Tesla using fast spin echo imaging. Br J Radiol (2003) 1.32
Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol (2000) 1.31
Lactating mothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient. Euro Surveill (2015) 1.28
Evaluation of a clinical case-definition of acquired immunodeficiency syndrome in Africa. Lancet (1987) 1.27
Poor performance of hepatitis C antibody tests in hospital patients in Uganda. J Med Virol (2010) 1.25
Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors. AIDS Care (2007) 1.25
Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int J Cancer (2000) 1.22
Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol (2000) 1.21
Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun (2005) 1.21
Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care (2007) 1.20
Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe. AIDS Care (2004) 1.19
Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther (2002) 1.19
Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol (2000) 1.18
Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. AIDS (2000) 1.18
Initiating antiretroviral treatment in a resource-constrained setting: does clinical staging effectively identify patients in need? Int J STD AIDS (2009) 1.18
T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol (2000) 1.17
Persistent diarrhea, strongly associated with HIV infection in Kinshasa, Zaire. Am J Gastroenterol (1987) 1.17
Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg (2000) 1.17
Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection. J Clin Immunol (1991) 1.15
Evaluation of multiplex real-time PCR for detection of Haemophilus ducreyi, Treponema pallidum, herpes simplex virus type 1 and 2 in the diagnosis of genital ulcer disease in the Rakai District, Uganda. Sex Transm Infect (2008) 1.14
Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis (2001) 1.13
Performance-based exposure control limits for pharmaceutical active ingredients. Am Ind Hyg Assoc J (1996) 1.11
Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat (2009) 1.10
Male partner voluntary counselling and testing associated with the antenatal services in Kinshasa, Democratic Republic of Congo: a randomized controlled trial. Int J STD AIDS (2011) 1.10
An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther (2008) 1.09
Mortality and morbidity in agriculture in the United States. J Agric Saf Health (2002) 1.09
Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol (2001) 1.08
Early changes in water diffusion, perfusion, T1, and T2 during focal cerebral ischemia in the rat studied at 8.5 T. Magn Reson Med (1999) 1.08
Reply to Gonzalez and Everall: Lest we forget: neuropsychiatry and the new generation anti-HIV drugs. AIDS (1999) 1.08
Occult hepatitis B viral DNA in liver carcinomas from a region with a low prevalence of chronic hepatitis B infection. J Viral Hepat (2004) 1.07
Sexual dysfunction with protease inhibitors. Lancet (1999) 1.07
High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg (1994) 1.07
Central nervous system myelin: structure, function, and pathology. Clin Biochem (1991) 1.07
Families affected by HIV: parents' and children's characteristics and disclosure to the children. AIDS Care (2004) 1.06
Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes. Antimicrob Agents Chemother (1997) 1.06
Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection. Clin Exp Immunol (1999) 1.05
Treatment and prevention of multidrug-resistant tuberculosis. Drugs (1999) 1.05
Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin Infect Dis (1997) 1.04
Mitochondrial genome organization and expression associated with cytoplasmic male sterility in sunflower (Helianthus annuus). Plant J (1991) 1.04
Altered receptor expression and decreased sensitivity of T-cells to the stimulatory cytokines IL-2, IL-7 and IL-12 in HIV infection. Immunol Lett (1998) 1.04
Hospital based clinical surveillance for dengue haemorrhagic fever in Bandung, Indonesia 1994-1995. Acta Trop (2001) 1.04
Evaluation of the WHO clinical case definition for AIDS in rural Zaire. AIDS (1988) 1.04
Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda. J Med Virol (2010) 1.03
A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology (1999) 1.03
Clinical characterization of a competitive PCR assay for quantitative testing of hepatitis C virus. J Clin Microbiol (1996) 1.01
Uptake of provider-initiated counselling and testing among tuberculosis suspects, Ethiopia. Int J Tuberc Lung Dis (2010) 1.01
Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy. Int J Tuberc Lung Dis (2011) 1.01